JP2018530554A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018530554A5 JP2018530554A5 JP2018517255A JP2018517255A JP2018530554A5 JP 2018530554 A5 JP2018530554 A5 JP 2018530554A5 JP 2018517255 A JP2018517255 A JP 2018517255A JP 2018517255 A JP2018517255 A JP 2018517255A JP 2018530554 A5 JP2018530554 A5 JP 2018530554A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic agent
- cancer
- tumor
- tumors
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562236280P | 2015-10-02 | 2015-10-02 | |
| US62/236,280 | 2015-10-02 | ||
| PCT/US2016/054924 WO2017059319A2 (en) | 2015-10-02 | 2016-09-30 | Combination therapy of bromodomain inhibitors and checkpoint blockade |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018530554A JP2018530554A (ja) | 2018-10-18 |
| JP2018530554A5 true JP2018530554A5 (OSRAM) | 2019-11-07 |
Family
ID=57137298
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018517255A Pending JP2018530554A (ja) | 2015-10-02 | 2016-09-30 | ブロモドメイン阻害薬及びチェックポイント阻害薬による併用療法 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20190192532A1 (OSRAM) |
| EP (1) | EP3355922A2 (OSRAM) |
| JP (1) | JP2018530554A (OSRAM) |
| KR (1) | KR20180081507A (OSRAM) |
| CN (1) | CN108289957A (OSRAM) |
| AR (1) | AR107500A1 (OSRAM) |
| AU (1) | AU2016331190A1 (OSRAM) |
| BR (1) | BR112018006689A2 (OSRAM) |
| CA (1) | CA2999523A1 (OSRAM) |
| CL (1) | CL2018000853A1 (OSRAM) |
| HK (1) | HK1256269A1 (OSRAM) |
| IL (1) | IL258212A (OSRAM) |
| MA (1) | MA43037A (OSRAM) |
| MX (1) | MX2018003824A (OSRAM) |
| PE (1) | PE20181068A1 (OSRAM) |
| WO (1) | WO2017059319A2 (OSRAM) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3130350A1 (en) * | 2005-06-08 | 2017-02-15 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1)pathway |
| KR101803099B1 (ko) | 2008-05-16 | 2017-11-30 | 타이가 바이오테크놀로지스, 인코포레이티드 | 항체 및 그 제조 방법 |
| ES2681478T3 (es) | 2008-08-28 | 2018-09-13 | Taiga Biotechnologies, Inc. | Moduladores de MYC, métodos de uso de los mismos y métodos para identificar agentes que modulan MYC |
| CA2799403C (en) | 2010-05-14 | 2020-01-21 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating leukemia |
| HUE031073T2 (en) | 2010-05-14 | 2017-06-28 | Dana Farber Cancer Inst Inc | Thieno triazolo-diazepine compounds for the treatment of neoplasia |
| EP2877189B1 (en) | 2012-07-20 | 2021-01-06 | Taiga Biotechnologies, Inc. | Enhanced reconstitution and autoreconstitution of the hematopoietic compartment |
| RU2016122654A (ru) | 2013-11-08 | 2017-12-14 | Дана-Фарбер Кэнсер Инститьют, Инк. | Комбинированная терапия злокачественной опухоли с использованием ингибиторов бромодоменового и экстратерминального (вет) белка |
| CA2940472A1 (en) | 2014-02-28 | 2015-09-03 | Tensha Therapeutics, Inc. | Treatment of conditions associated with hyperinsulinaemia |
| EA033325B1 (ru) | 2014-10-27 | 2019-09-30 | Тэнша Терапеутикс, Инк. | Ингибиторы бромодомена |
| MA45123A (fr) | 2016-05-27 | 2019-04-10 | Agenus Inc | Anticorps anti-tim-3 et leurs méthodes d'utilisation |
| EP4242298A2 (en) | 2016-12-02 | 2023-09-13 | Taiga Biotechnologies, Inc. | Nanoparticle formulations |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| WO2019140953A1 (zh) * | 2018-01-16 | 2019-07-25 | 深圳市塔吉瑞生物医药有限公司 | 用于抑制激酶活性的二苯氨基嘧啶类化合物 |
| WO2020010227A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| WO2020051571A1 (en) * | 2018-09-07 | 2020-03-12 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Brd4-jak2 inhibitors |
| TWI816881B (zh) * | 2018-09-13 | 2023-10-01 | 大陸商恒翼生物醫藥（上海）股份有限公司 | 用於治療三陰性乳癌之組合療法 |
| US11352350B2 (en) | 2018-11-30 | 2022-06-07 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
| CN109666723B (zh) * | 2019-01-22 | 2022-04-15 | 南通大学 | 一种基于pdl1/pdl2超增强子的免疫检测点抑制剂的应用 |
| AU2020272664A1 (en) | 2019-04-08 | 2021-11-04 | Taiga Biotechnologies, Inc. | Compositions and methods for the cry opreservation of immune cells |
| AU2020274117A1 (en) * | 2019-05-14 | 2021-12-02 | Taiga Biotechnologies, Inc. | Compositions and methods for treating T cell exhaustion |
| US20230093080A1 (en) * | 2019-07-15 | 2023-03-23 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| JP7502811B2 (ja) * | 2019-11-05 | 2024-06-19 | レスバーロジックス コーポレイション | Ｂｅｔブロモドメイン阻害物質およびナトリウム依存性グルコース輸送体２阻害物質の組み合わせで主要な心血管有害事象（ｍａｃｅ）を処置および／または予防する方法 |
| US20230053152A1 (en) * | 2019-11-26 | 2023-02-16 | Benobio Co., Ltd. | Novel Quercetin Redox Derivative And Use Thereof As BET Inhibitor |
| EP4076520A4 (en) | 2019-12-17 | 2024-03-27 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| WO2021175432A1 (en) | 2020-03-04 | 2021-09-10 | Boehringer Ingelheim International Gmbh | Method for administration of an anti cancer agent |
| TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
| WO2021257857A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Naphthyridinone compounds as jak2 v617f inhibitors |
| WO2021257863A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Pyrrolotriazine compounds as jak2 v617f inhibitors |
| WO2022006457A1 (en) | 2020-07-02 | 2022-01-06 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
| US11767323B2 (en) | 2020-07-02 | 2023-09-26 | Incyte Corporation | Tricyclic pyridone compounds as JAK2 V617F inhibitors |
| WO2022046989A1 (en) | 2020-08-27 | 2022-03-03 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
| US11919908B2 (en) | 2020-12-21 | 2024-03-05 | Incyte Corporation | Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors |
| TW202241891A (zh) | 2020-12-30 | 2022-11-01 | 美商凱麥拉醫療公司 | Irak降解劑及其用途 |
| JP2024506656A (ja) | 2021-02-15 | 2024-02-14 | カイメラ セラピューティクス， インコーポレイテッド | Ｉｒａｋ４分解剤およびその使用 |
| WO2022182839A1 (en) | 2021-02-25 | 2022-09-01 | Incyte Corporation | Spirocyclic lactams as jak2 v617f inhibitors |
| WO2023076556A1 (en) | 2021-10-29 | 2023-05-04 | Kymera Therapeutics, Inc. | Irak4 degraders and synthesis thereof |
| JP2025504059A (ja) | 2022-01-31 | 2025-02-06 | カイメラ セラピューティクス， インコーポレイテッド | Ｉｒａｋデグレーダー及びその使用 |
| JP2025509672A (ja) | 2022-03-17 | 2025-04-11 | インサイト・コーポレイション | Ｊａｋ２ ｖ６１７ｆ阻害剤としての三環式尿素化合物 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2652304T3 (es) * | 2009-11-05 | 2018-02-01 | Glaxosmithkline Llc | Compuesto de benzodiacepina novedoso |
| WO2011143657A1 (en) * | 2010-05-14 | 2011-11-17 | Dana-Farber Cancer Institute, Inc. | Male contraceptive compositions and methods of use |
| JP5715241B2 (ja) * | 2010-05-14 | 2015-05-07 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | 新生物、炎症性疾患、およびその他の障害を治療するための組成物および方法 |
| HUE031073T2 (en) * | 2010-05-14 | 2017-06-28 | Dana Farber Cancer Inst Inc | Thieno triazolo-diazepine compounds for the treatment of neoplasia |
| WO2012075456A1 (en) * | 2010-12-02 | 2012-06-07 | Constellation Pharmaceuticals | Bromodomain inhibitors and uses thereof |
| WO2014128070A1 (de) * | 2013-02-22 | 2014-08-28 | Bayer Pharma Aktiengesellschaft | Pyrrolo- und pyrazolo-triazolodiazepine als bet-proteininhibitoren zur behandlung von hyper-proliferativen erkrankungen |
| HK1212345A1 (en) * | 2013-02-22 | 2016-06-10 | Bayer Pharma Aktiengesellschaft | 4-substituted pyrrolo- and pyrazolo-diazepines |
| EP2968263A2 (en) * | 2013-03-15 | 2016-01-20 | Genentech, Inc. | Treating th2-mediated diseases by inhibition of bromodomain-comprising proteins brd7 and brd9 |
| WO2015018522A1 (en) * | 2013-08-06 | 2015-02-12 | Oncoethix Sa | Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large b-cell lymphoma (dlbcl) |
| KR20160037201A (ko) * | 2013-08-06 | 2016-04-05 | 온코에틱스 게엠베하 | Bet-브로모도메인 억제제를 사용한 미만성 거대 b-세포 림프종 (dlbcl)의 치료 방법 |
| AU2014331697A1 (en) * | 2013-10-11 | 2016-05-05 | Constellation Pharmaceuticals, Inc. | Use of CBP/EP300 bromodomain inhibitors for cancer immunotherapy |
| MA39211B1 (fr) * | 2013-12-24 | 2019-01-31 | Bristol Myers Squibb Co | Composés tricycliques comme agents anti-cancers |
-
2016
- 2016-09-30 KR KR1020187012018A patent/KR20180081507A/ko not_active Withdrawn
- 2016-09-30 EP EP16781957.2A patent/EP3355922A2/en not_active Withdrawn
- 2016-09-30 AR ARP160103015A patent/AR107500A1/es unknown
- 2016-09-30 WO PCT/US2016/054924 patent/WO2017059319A2/en not_active Ceased
- 2016-09-30 PE PE2018000491A patent/PE20181068A1/es unknown
- 2016-09-30 MA MA043037A patent/MA43037A/fr unknown
- 2016-09-30 US US15/764,131 patent/US20190192532A1/en not_active Abandoned
- 2016-09-30 MX MX2018003824A patent/MX2018003824A/es unknown
- 2016-09-30 BR BR112018006689A patent/BR112018006689A2/pt not_active IP Right Cessation
- 2016-09-30 AU AU2016331190A patent/AU2016331190A1/en not_active Abandoned
- 2016-09-30 CN CN201680070462.8A patent/CN108289957A/zh active Pending
- 2016-09-30 CA CA2999523A patent/CA2999523A1/en not_active Abandoned
- 2016-09-30 HK HK18115329.0A patent/HK1256269A1/zh unknown
- 2016-09-30 JP JP2018517255A patent/JP2018530554A/ja active Pending
-
2018
- 2018-03-19 IL IL258212A patent/IL258212A/en unknown
- 2018-04-02 CL CL2018000853A patent/CL2018000853A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018530554A5 (OSRAM) | ||
| ZA202210065B (en) | Interleukin-21 muteins and methods of treatment | |
| MX2017012965A (es) | Anticuerpo anti-c-met y conjugado de farmaco citotoxico de anticuerpo anti-c-met y uso farmaceutico del mismo. | |
| PH12018501220A1 (en) | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof | |
| PH12021551487A1 (en) | Tumor-targeted agonistic cd28 antigen binding molecules | |
| IL265541B2 (en) | Bispecific antibodies and compounds containing them for the treatment of cancer | |
| MX2019009967A (es) | Moleculas de union biespecificas que son capaces de unirse a cd137 y a antigenos tumorales, y usos de las mismas. | |
| CL2024003715A1 (es) | Proteína de unión multiespecífica que se une a nkg2d, cd33 y cd16; composición; y uso. | |
| MX373927B (es) | Anticuerpos biespecíficos con funciones efectoras reducidas. | |
| EA202091590A1 (ru) | Антитела против pd-l1 и варианты их применения | |
| EA201891983A1 (ru) | Комбинированная терапия антителами к cd73 | |
| EP4219563A3 (en) | Methods of treating cancer with anti-pd-1 antibodies | |
| EA201791050A1 (ru) | Конъюгаты антител и лекарственных средств | |
| EA201691361A1 (ru) | Антитела к lag-3 для лечения гематологических злокачественных опухолей | |
| MX2019002474A (es) | Composiciones de agente de unión de portador-ligando-1 de muerte programada y métodos de uso de las mismas para el tratamiento de cánceres. | |
| JP2019501145A5 (OSRAM) | ||
| EA201892362A1 (ru) | Агонистические антитела, которые связываются с cd40 человека, и варианты их применения | |
| EA201890613A1 (ru) | Полипептиды, связывающие cd3 | |
| HRP20202042T1 (hr) | Modulacija tumorske imunosti | |
| EA201890158A1 (ru) | Антитела против ntb-a и связанные композиции и способы | |
| RU2016109811A (ru) | Лечение рака комбинацией антагониста pd-1 и динациклиба | |
| JOP20190187A1 (ar) | مترافقات عقار جسم مضاد لـ ccr7 | |
| FI3036258T3 (fi) | Immunoreseptorin modulointi syövän ja virusinfektioiden hoitamiseksi | |
| EA201491265A1 (ru) | Соединения для ингибирования взаимодействия bcl-2 с партнерами по связыванию | |
| EA201491264A1 (ru) | Соединения для ингибирования взаимодействия bcl-2 с партнерами по связыванию |